WELCOME TO BIOSION
Biosion is a clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® high-throughput endocytosis platform, and Flexibody® bispecific platform. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and atopic dermatitis, with 4 other assets in the clinic with our partners. Biosion has operations in the US, Australia and China. For more information, please visit www.biosion.com.
COMPANY CULTURE

  • Mission

    To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide

    Mission

    To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide

  • Vision

    To deliver breakthrough therapeutics to patients globally

    Vision

    Delivering Breakthrough Antibody-Based Therapeutics to Patients Globally

  • Culture

    Patients ∙ Employee ∙ Society ∙ Synergy ∙ Adeptness ∙ Integrity

    Culture

    Patients ∙ Employee ∙ Society ∙ Synergy ∙ Adeptness ∙ Integrity

OUR LEADERSHIP
EXECUTIVE TEAM
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Mingjiu Chen, Ph.D
    Chief Executive Officer & Founder
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Qi Liu, MD, Ph.D.
  • Hugh M. Davis, Ph.D.
    Chief Business & Development Officer, and President of Biosion USA
  • Jonathan Silverberg, M.D., Ph.D.
  • Anthony Yeh, Ph.D.
    Chief Strategy Officer & Head of China BD
  • Steven Knapp，Pharm.D.
    Chief Regulatory and Quality Officer
  • Jonathan Silverberg, M.D., Ph.D.
  • Tariq Ghayur, Ph.D.
  • Tariq Ghayur, Ph.D.
  • Rakesh Dixit, Ph.D., DABT
  • Anderson Zhang, MBA
    Head of Finance
  • Furqan Ahmed, Pharm.D.
    Head of Business Development
  • Rakesh Dixit, Ph.D., DABT
  • Melody Wang, J.D., Esq.
    Head of Legal Affairs and Board Secretary
ADVISORY BOARD
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Mingjiu Chen, Ph.D
    Chief Executive Officer & Founder
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Qi Liu, MD, Ph.D.
  • Hugh M. Davis, Ph.D.
    Chief Business & Development Officer, and President of Biosion USA
  • Jonathan Silverberg, M.D., Ph.D.
  • Anthony Yeh, Ph.D.
    Chief Strategy Officer & Head of China BD
  • Steven Knapp，Pharm.D.
    Chief Regulatory and Quality Officer
  • Jonathan Silverberg, M.D., Ph.D.
  • Tariq Ghayur, Ph.D.
  • Tariq Ghayur, Ph.D.
  • Rakesh Dixit, Ph.D., DABT
  • Anderson Zhang, MBA
    Head of Finance
  • Furqan Ahmed, Pharm.D.
    Head of Business Development
  • Rakesh Dixit, Ph.D., DABT
  • Melody Wang, J.D., Esq.
    Head of Legal Affairs and Board Secretary
CONTACT

Biosion Australia Pty Ltd

Early Clinical Development

Biosion Australia

58 Gipps Street Collingwood, Victoria 3066 Australia

Tel：1-302-257-5085

Email：BD@Biosion.com

Biosion, Inc.

China Business Development and Clinical Hub

Biosion China - Shanghai

Global Discovery and Development Center

Biosion China - Nanjing （HQ）

Building D, Zhongdan Unit, Nanjing Jiangbei New Area, China 210061

Tel：86-25-5829-1977

Fax：86-25-8650-7191

Email：BD@Biosion.com

Biosion USA, Inc.

Global Business Development Hub

Biosion USA - SoCal

Global Clinical Development Hub

Biosion USA - Philadelphia

1 Innovation Way, Suite 300, Newark, Delaware 19711, USA

Tel：1-302-257-5085

Email：BD@Biosion.com

Email Us
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
Email: BD@Biosion.com
Tel: 1-302-257-5085
PRIVACY NOTICE
TERMS OF USE
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-257-5085
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
WELCOME TO BIOSION
Biosion is a clinical-stage biotechnology company committed to developing breakthrough antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® high-throughput endocytosis platform, and Flexibody® bispecific platform. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and atopic dermatitis, with 4 other assets in the clinic with our partners. Biosion has operations in the US, Australia and China. For more information, please visit www.biosion.com.

  • MISSION

    To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide

  • VISION

    Delivering Breakthrough Antibody-Based Therapeutics to Patients Globally

  • CULTURE

    Patients
    Employee
    Society
    Synergy
    Adeptness
    Integrity
EXECUTIVE TEAM
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Mingjiu Chen, Ph.D
    Chief Executive Officer & Founder
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Qi Liu, MD, Ph.D.
  • Hugh M. Davis, Ph.D.
    Chief Business & Development Officer, and President of Biosion USA
  • Jonathan Silverberg, M.D., Ph.D.
  • Anthony Yeh, Ph.D.
    Chief Strategy Officer & Head of China BD
  • Steven Knapp，Pharm.D.
    Chief Regulatory and Quality Officer
  • Jonathan Silverberg, M.D., Ph.D.
  • Tariq Ghayur, Ph.D.
  • Tariq Ghayur, Ph.D.
  • Rakesh Dixit, Ph.D., DABT
  • Anderson Zhang, MBA
    Head of Finance
  • Furqan Ahmed, Pharm.D.
    Head of Business Development
  • Rakesh Dixit, Ph.D., DABT
  • Melody Wang, J.D., Esq.
    Head of Legal Affairs and Board Secretary
DEVELOPMENT TEAM
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Mingjiu Chen, Ph.D
    Chief Executive Officer & Founder
  • Lei Zheng, MD, Ph.D.
    Advisory Board Chair
  • Qi Liu, MD, Ph.D.
  • Hugh M. Davis, Ph.D.
    Chief Business & Development Officer, and President of Biosion USA
  • Jonathan Silverberg, M.D., Ph.D.
  • Anthony Yeh, Ph.D.
    Chief Strategy Officer & Head of China BD
  • Steven Knapp，Pharm.D.
    Chief Regulatory and Quality Officer
  • Jonathan Silverberg, M.D., Ph.D.
  • Tariq Ghayur, Ph.D.
  • Tariq Ghayur, Ph.D.
  • Rakesh Dixit, Ph.D., DABT
  • Anderson Zhang, MBA
    Head of Finance
  • Furqan Ahmed, Pharm.D.
    Head of Business Development
  • Rakesh Dixit, Ph.D., DABT
  • Melody Wang, J.D., Esq.
    Head of Legal Affairs and Board Secretary
COPYRIGHT © 2023.
BIOSION ALL RIGHTS RESERVED.
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
Email: BD@Biosion.com
Tel: 1-302-257-5085
PRIVACY NOTICE
TERMS OF USE
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-257-5085
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号